TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
Clinical safety rating: safe
Animal studies have demonstrated safety
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
| Metabolism | Triprolidine: Hepatic metabolism via hydroxylation and conjugation. Pseudoephedrine: Partially metabolized in the liver by N-demethylation to an inactive metabolite; primarily excreted unchanged in urine. |
| Excretion | Triprolidine: Renal excretion of metabolites (approx. 60%) and unchanged drug (less than 5%). Pseudoephedrine: Primarily renal elimination as unchanged drug (70-90%), with minor hepatic metabolism. Fecal excretion is negligible for both. |
| Half-life | Triprolidine: 5-7 hours. Pseudoephedrine: 4-8 hours (pH-dependent; alkaline urine prolongs half-life). Clinical context: Dose adjustment needed in renal impairment for pseudoephedrine. |
| Protein binding | Triprolidine: Approximately 90% bound to plasma proteins (mainly albumin). Pseudoephedrine: Minimal protein binding, approximately 20%. |
| Volume of Distribution | Triprolidine: 2-3 L/kg. Pseudoephedrine: 2.6-3.5 L/kg. Clinical meaning: Indicates extensive tissue distribution. |
| Bioavailability | Triprolidine: Oral bioavailability ~90%. Pseudoephedrine: Oral bioavailability ~100%. |
| Onset of Action | Both components: Oral administration, 30-60 minutes. |
| Duration of Action | Triprolidine: 4-6 hours. Pseudoephedrine: 4-6 hours (up to 8 hours with extended-release formulations). Clinical note: Effect may persist longer in patients with alkaline urine. |
| Molecular Weight | Triprolidine hydrochloride: 314.6 Da; Pseudoephedrine hydrochloride: 201.7 Da; combination product: molecular weight of the two hydrochlorides. |
| Action Class | Antihistamine and Nasal Decongestant Combination |
1 capsule (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4-6 hours; not to exceed 4 doses in 24 hours.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-50 mL/min: administer every 6-8 hours; GFR 10-29 mL/min: administer every 12 hours; GFR <10 mL/min: not recommended (avoid). |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: cautious use, consider dose reduction; Child-Pugh Class C: contraindicated. |
| Pediatric use | Children 12 years and older: same as adult; Children 6-12 years: 1/2 capsule (triprolidine 1.25 mg/pseudoephedrine 30 mg) every 6 hours; Children 2-6 years: not recommended (safety not established). |
| Geriatric use | Initiate with 1 capsule every 8 hours, monitor for anticholinergic effects and hypertension; avoid in patients over 65 years with significant cardiovascular conditions. |
| 1st trimester | Limited human data; based on animal studies and lack of teratogenicity, use only if clearly needed. First trimester risks not fully excluded. |
| 2nd trimester | Use with caution; potential for maternal tachycardia and hypertension which may reduce uteroplacental blood flow. |
| 3rd trimester | Avoid near term; pseudoephedrine may cause uterine vasoconstriction and reduce uterine blood flow; also may cause irritability or tachycardia in neonate. |
Clinical note
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
| Placental transfer | Both components cross the placenta. Pseudoephedrine reaches fetal concentrations approximately 70% of maternal levels based on animal data. |
| Breastfeeding | Both triprolidine and pseudoephedrine are excreted into breast milk in small amounts. Pseudoephedrine may cause irritability or drowsiness in the infant. Dose-dependent reduction in milk production has been reported with pseudoephedrine. Use with caution and monitor infant for adverse effects. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Sedation |
| Serious Effects | Hypertension, Tachycardia, Arrhythmias, Stroke, Seizures, Urinary retention, Acute angle-closure glaucoma, Severe allergic reactions (anaphylaxis) |
Severe hypertensionCoronary artery diseaseConcurrent MAOI therapy (or within 14 days)Narrow-angle glaucomaUrinary retentionSevere renal impairment (CrCl < 30 mL/min)
| Precautions | Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias, Central nervous system stimulation: May cause insomnia, dizziness, or nervousness, Anticholinergic effects: Caution in patients with glaucoma, prostatic hypertrophy, or urinary retention, Drug interactions: Avoid concurrent use with MAOIs or within 14 days of stopping them, Geriatric use: Increased sensitivity to anticholinergic effects |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data suggests risk but benefits may outweigh risks. |
| Teratogenic Risk | First trimester: Limited human data; animal studies not suggestive of teratogenicity. Avoid due to theoretical risk of vascular disruption from pseudoephedrine. Second/third trimester: Pseudoephedrine may reduce uteroplacental blood flow; association with gastroschisis in some studies. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; fetal heart rate monitoring during prolonged use. Assess for signs of uterine artery constriction (e.g., decreased fetal movements). |
| Fertility Effects | No definitive human data. In animal studies, no significant impairment of fertility at clinically relevant doses. |
| Avoid high-tyramine foods (aged cheeses, cured meats, soy products) as pseudephedrine may increase risk of hypertensive crisis with MAOIs. Avoid excessive caffeine (coffee, tea, cola) to prevent additive stimulant effects. Grapefruit juice may alter metabolism, but interaction is minimal. |
| Clinical Pearls | Triprolidine is a first-generation antihistamine with sedative effects; pseudephedrine is a sympathomimetic decongestant. Caution in hypertension, hyperthyroidism, and BPH. Triprolidine may cause anticholinergic effects; avoid in narrow-angle glaucoma. Use with caution in elderly due to fall risk. |
| Patient Advice | May cause drowsiness; avoid driving or operating heavy machinery until you know how the medicine affects you. · Do not use if you have taken an MAOI in the last 14 days. · Limit caffeine intake to reduce nervousness or insomnia. · Avoid alcohol as it increases drowsiness and dizziness. · Do not exceed recommended dosage to prevent serious side effects like rapid heart rate or seizures. |